355 related articles for article (PubMed ID: 27038332)
1. Bioresorbable vascular scaffolds for small vessels coronary disease: The BVS-save registry.
Latini RA; Granata F; Ielasi A; Varricchio A; Moscarella E; Tespili M; Cortese B
Catheter Cardiovasc Interv; 2016 Sep; 88(3):380-7. PubMed ID: 27038332
[TBL] [Abstract][Full Text] [Related]
2. Long-Term Clinical Outcomes After Bioresorbable Vascular Scaffold Implantation for the Treatment of Coronary In-Stent Restenosis: A Multicenter Italian Experience.
Moscarella E; Ielasi A; Granata F; Coscarelli S; Stabile E; Latib A; Cortese B; Tespili M; Tanaka A; Capozzolo C; Caliendo L; Colombo A; Varricchio A
Circ Cardiovasc Interv; 2016 Apr; 9(4):e003148. PubMed ID: 27059683
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcomes of bioresorbable vascular scaffold to treat all-comer patients. Are patients with acute coronary syndrome better candidates for bioresorbable vascular scaffold?
Picard F; Avram R; Marquis-Gravel G; Tadros VX; Ly HQ; Dorval JF; Doucet S; Gosselin G; Asgar AW; Ibrahim R; Bonan R; de Hemptinne Q; Nosair M; L-L'Allier P; Tanguay JF
Cardiovasc Revasc Med; 2019 Mar; 20(3):228-234. PubMed ID: 30075958
[TBL] [Abstract][Full Text] [Related]
4. Direct bioresorbable vascular scaffold implantation: Feasibility and midterm results.
Suárez de Lezo J; Martín P; Mazuelos F; Nóvoa J; Ojeda S; Pan M; Segura J; Hernández E; Romero M; Melián F; Medina A; Suárez de Lezo J
Catheter Cardiovasc Interv; 2016 Apr; 87(5):E173-82. PubMed ID: 26268440
[TBL] [Abstract][Full Text] [Related]
5. Clinical, Angiographic, Functional, and Imaging Outcomes 12 Months After Implantation of Drug-Eluting Bioresorbable Vascular Scaffolds in Acute Coronary Syndromes.
Gori T; Schulz E; Hink U; Kress M; Weiers N; Weissner M; Jabs A; Wenzel P; Capodanno D; Münzel T
JACC Cardiovasc Interv; 2015 May; 8(6):770-777. PubMed ID: 25999097
[TBL] [Abstract][Full Text] [Related]
6. Five-year clinical and functional multislice computed tomography angiographic results after coronary implantation of the fully resorbable polymeric everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB cohort A trial.
Onuma Y; Dudek D; Thuesen L; Webster M; Nieman K; Garcia-Garcia HM; Ormiston JA; Serruys PW
JACC Cardiovasc Interv; 2013 Oct; 6(10):999-1009. PubMed ID: 24156961
[TBL] [Abstract][Full Text] [Related]
7. Angiographic and clinical outcomes of patients treated with everolimus-eluting bioresorbable stents in routine clinical practice: Results of the ISAR-ABSORB registry.
Hoppmann P; Kufner S; Cassese S; Wiebe J; Schneider S; Pinieck S; Scheler L; Bernlochner I; Joner M; Schunkert H; Laugwitz KL; Kastrati A; Byrne RA
Catheter Cardiovasc Interv; 2016 Apr; 87(5):822-9. PubMed ID: 26708019
[TBL] [Abstract][Full Text] [Related]
8. Mid- to long-term outcome of patients treated with everolimus-eluting bioresorbable vascular scaffolds: Data of the BVS registry Göttingen predominantly from ACS patients.
Hellenkamp K; Becker A; Gabriel YD; Hasenfuß G; Hünlich M; Jacobshagen C; Schillinger W; Schroeter MR
Int J Cardiol; 2017 May; 234():58-63. PubMed ID: 28258843
[TBL] [Abstract][Full Text] [Related]
9. Bioresorbable Everolimus-Eluting Vascular Scaffold for Long Coronary Lesions: A Subanalysis of the International, Multicenter GHOST-EU Registry.
Geraci S; Kawamoto H; Caramanno G; Ruparelia N; Capodanno D; Brugaletta S; Gori T; Nef H; Sabate M; Mehilli J; Lesiak M; Naber C; Di Mario C; Capranzano P; Wiebe J; Araszkiewicz A; Pyxaras S; Mattesini A; Münzel T; Tamburino C; Colombo A; Latib A
JACC Cardiovasc Interv; 2017 Mar; 10(6):560-568. PubMed ID: 28259663
[TBL] [Abstract][Full Text] [Related]
10. Mid- to Long-Term Clinical Outcomes of Patients Treated With the Everolimus-Eluting Bioresorbable Vascular Scaffold: The BVS Expand Registry.
Felix CM; Fam JM; Diletti R; Ishibashi Y; Karanasos A; Everaert BR; van Mieghem NM; Daemen J; de Jaegere PP; Zijlstra F; Regar ES; Onuma Y; van Geuns RJ
JACC Cardiovasc Interv; 2016 Aug; 9(16):1652-63. PubMed ID: 27476094
[TBL] [Abstract][Full Text] [Related]
11. A prospective evaluation of a standardized strategy for the use of a polymeric everolimus-eluting bioresorbable scaffold in ST-segment elevation myocardial infarction: Rationale and design of the BVS STEMI STRATEGY-IT study.
Ielasi A; Varricchio A; Campo G; Leoncini M; Cortese B; Vicinelli P; Brugaletta S; di Uccio FS; Latib A; Tespili M
Catheter Cardiovasc Interv; 2017 Jun; 89(7):1129-1138. PubMed ID: 27774758
[TBL] [Abstract][Full Text] [Related]
12. Scaffold Thrombosis After Percutaneous Coronary Intervention With ABSORB Bioresorbable Vascular Scaffold: A Systematic Review and Meta-Analysis.
Lipinski MJ; Escarcega RO; Baker NC; Benn HA; Gaglia MA; Torguson R; Waksman R
JACC Cardiovasc Interv; 2016 Jan; 9(1):12-24. PubMed ID: 26762906
[TBL] [Abstract][Full Text] [Related]
13. Clinical outcomes following target lesion revascularization for bioresorbable scaffold failure.
Tanaka A; Ruparelia N; Kawamoto H; Sticchi A; Figini F; Carlino M; Chieffo A; Montorfano M; Latib A; Colombo A
Catheter Cardiovasc Interv; 2016 Apr; 87(5):832-6. PubMed ID: 26331577
[TBL] [Abstract][Full Text] [Related]
14. Clinical Comparison With Short-Term Follow-Up of Bioresorbable Vascular Scaffold Versus Everolimus-Eluting Stent in Primary Percutaneous Coronary Interventions.
Cortese B; Ielasi A; Romagnoli E; Varricchio A; Cuculo A; Loi B; Pisano F; Corrado D; Sesana M; La Vecchia L; Summaria F; Tespili M; Silva Orrego P; Tognoni G; Steffenino G
Am J Cardiol; 2015 Sep; 116(5):705-10. PubMed ID: 26100584
[TBL] [Abstract][Full Text] [Related]
15. A next-generation bioresorbable coronary scaffold system: from bench to first clinical evaluation: 6- and 12-month clinical and multimodality imaging results.
Verheye S; Ormiston JA; Stewart J; Webster M; Sanidas E; Costa R; Costa JR; Chamie D; Abizaid AS; Pinto I; Morrison L; Toyloy S; Bhat V; Yan J; Abizaid A
JACC Cardiovasc Interv; 2014 Jan; 7(1):89-99. PubMed ID: 24139932
[TBL] [Abstract][Full Text] [Related]
16. Clinical and angiographic outcome of a single center, real world population treated with a dedicated technique of implantation for bioresorbable vascular scaffolds. The FAtebenefratelli Bioresorbable Vascular Scaffold (FABS) registry.
Cortese B; di Palma G; Cerrato E; Latini RA; Elwany M; Orrego PS; Seregni RG
J Interv Cardiol; 2017 Oct; 30(5):427-432. PubMed ID: 28853189
[TBL] [Abstract][Full Text] [Related]
17. A hybrid strategy with bioresorbable vascular scaffolds and drug eluting stents for treating complex coronary lesions.
Jabbour RJ; Ielasi A; Tanaka A; Leoncini M; Cortese B; Grigis G; Mitomo S; Regazzoli D; Di Palma G; Rapetto C; Tespili M; Colombo A; Latib A
Cardiovasc Revasc Med; 2017; 18(5S1):S4-S9. PubMed ID: 28314675
[TBL] [Abstract][Full Text] [Related]
18. Everolimus-eluting bioresorbable scaffold implantation for the treatment of bifurcation lesions - Implications from early clinical experience during daily practice.
Wiebe J; Dörr O; Bauer T; Liebetrau C; Boeder N; Möllmann H; Hamm CW; Nef HM
Cardiovasc Revasc Med; 2016; 17(5):313-7. PubMed ID: 27085220
[TBL] [Abstract][Full Text] [Related]
19. Applicability and procedural success rate of bioresorbable -vascular scaffolds for percutaneous coronary intervention in an all-comer cohort of 383 consecutive patients.
Schlundt C; Achenbach S; Felten F; Roether J; Marwan M; Nef H; Ludwig J; Tröbs M
Acta Cardiol; 2017 Aug; 72(4):425-432. PubMed ID: 28705057
[TBL] [Abstract][Full Text] [Related]
20. The relationship of pre-procedural Dmax based sizing to lesion level outcomes in Absorb BVS and Xience EES treated patients in the AIDA trial.
Tijssen RYG; Kerkmeijer LSM; Katagiri Y; Kraak RP; Takahashi K; Kogame N; Chichareon P; Modolo R; Asano T; Nassif M; Kalkman DN; Sotomi Y; Collet C; Hofma SH; van der Schaaf RJ; Arkenbout EK; Weevers APJD; Beijk MAM; Piek JJ; Tijssen JGP; Henriques JP; de Winter RJ; Onuma Y; Serruys PW; Wykrzykowska JJ
Int J Cardiovasc Imaging; 2019 Jul; 35(7):1189-1198. PubMed ID: 30911857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
